Study finds stroke risk from anemia drug Aranesp

By MARILYNN MARCHIONE - AP Medical Writer - Associated Press Friday, October 30, 2024

Loading...

A new study raises fresh safety concerns about widely used anemia medicines, finding that the drug Aranesp nearly doubled the risk of stroke in people with diabetes and chronic kidney problems who are not yet sick enough to need dialysis.

The study is the largest ever of these blood-boosting drugs and the only one that compared them to a dummy treatment. The medicines have become blockbuster sellers because they lessen the need for transfusions, but their ability to prevent heart attacks, kidney failure or other problems have not been proven.

Over the last two years, the federal Food and Drug Administration has repeatedly strengthened warning labels on Aranesp, Epogen and Procrit as concerns rose that they may worsen survival in certain cancer patients, especially at higher doses. Amgen Inc. of Thousand Oaks, California, makes all three drugs, although New Brunswick, New Jersey-based Johnson & Johnson sells Procrit.

The new study tested Aranesp in a different group of patients: 4,038 people with Type 2 diabetes, kidney problems and moderate anemia — problems that often go hand in hand. The goal was to see if the drug could prevent heart attacks, heart failure, strokes or the need for dialysis.

It not only failed to do that, but "we uncovered a risk that I think is substantial for stroke," said study leader Dr. Marc Pfeffer, a heart specialist at Brigham and Women's Hospital in Boston.

Strokes occurred in 101 patients given Aranesp and 53 patients given dummy shots. Looked at another way, the risk of suffering a stroke was about 1 percent per year in the placebo group and about 2 percent in those given Aranesp.

For many people, "this risk will outweigh its potential benefits," the study's authors conclude.

Results were published online Friday by the New England Journal of Medicine and were to be presented at a conference of kidney specialists in San Diego. Amgen sponsored the study. Pfeffer has consulted for the company and two authors work for it.

Dr. Roger Perlmutter, Amgen's head of research and development, said the magnitude of stroke risk "surprised us." The potential risk of stroke has been listed on Aranesp's label since the drug was approved in 2001, but "we will definitely update the label" because of the new study's results, he said.

Aranesp did reduce the need for transfusions — 297 people on the drug needed them versus 496 of those getting dummy shots. However, there was only a modest improvement in how fatigued people said they felt in the Aranesp group.

The study's results may not apply to people already on dialysis, Dr. Philip Marsden of St. Michael's Hospital and the University of Toronto in Ontario, Canada, writes in an editorial in the medical journal. For them, the quality of life improvement from fewer transfusions may be greater.

Also on Friday, the New York Attorney General's office said it and 15 states were suing Amgen, claiming the company gave kickbacks and weekend retreats to medical providers to help boost Aranesp sales, and encouraged them to bill third parties, including Medicaid, even though the drug was available to them at no cost.

A statement by the company said the allegations were "without merit."

Join the Discussion
Rate Article: Average 0 out of 5
register or log in to comment on this article!

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

Research Exchange

Meeting the Challenges of Long-term Time-lapse Imaging

Oct 26

Recent technological developments in the sequence capture of cellular events through a light microscope can be combined to image multiple independent experiments automatically, with many advantages.

Handle With Care

Aug 26

Researchers face the dual challenges of difficult to handle and hard to maintain stem cells.

Six Tips for More Successful Cell Cultures

Aug 18

For those who perform cell culture experiments, it pays to be meticulous. Even seemingly minor handling techniques and lab equipment features can make a difference in achieving success.

Rapid Generation of Assay-ready Serial Dilution Plates Using Two-stage Low Volume Pipetting

Jul 22

Researchers see the benefits of streamlining accurate serial dilution of stock solutions of compounds. By Joby Jenkins, TTP LabTech As the cost of drug development escalates there is a growing requirement to accelerate the R&D cycle and eliminate unwanted off-target drug effects earlier.

The Future of the FDA: Operating in an Electronic World

Oct 12

Acording to an Axendia reseach study, the FDA is currently shifting its organizational and technology infrastructures to facilitate electronic interactions with the companies it regulates.

Tissue Microarrays - Opening up new opportunities in the Therapeutics sector

Oct 12

Tissue Microarray has become a pivotal cog in the wheel for high throughput studies and is an integral part in the validation process for screening results from discovery platforms for expression studies using various approaches.

Translational Informatics for Systems Biology

Oct 12

A study in which IO Informatics' Sentient software has been applied to integrating and linking a customer's multiple data streams.

De Novo Formula Generation with Sub-ppm Confidence

Oct 12

Novel technology embodied in the micrOTOF allows precise measurement of both accurate mass and True Isotopic Pattern (TIP) over a wide dynamic range, allowing for the implementation of an open access system.

ADP-Glo™: An Ideal Approach to Monitor the Activity of Protein Kinases and Beyond

Oct 16

Because of its versatility (alltypesofsubstrates), robustness (Z’>0.8), rapidperformance, and its ease of use, the luminescence based Kinase Glo® assay platform has gained wide acceptance in many drug screening programs for protein kinase inhibitors.

A Cell-Based, Microplate Format, DELFIA Assay for Determination of the Activation of MAP KinaseSofia

Oct 16

Mitogen-activated protein kinases(MAPK) are activated in response to extracellularsignals or cellular stress. We have set up a cell-based DELFIA®Time-Resolved Fluorescence assay to test compounds or conditions for their ability to modulate cellular stress by the activation of MAPK.

Cell Based Assays for Studying the Effects of Cytotoxic Agents

Oct 16

Apoptosis, DNA fragmentation and cell proliferation are important parameters when studying live cell function, especially, when the effects of cytotoxic agents are under study.

Input normalization by global feedforward inhibition expands cortical dynamic range

2 hours ago

The cortex is sensitive to weak stimuli, but responds to stronger inputs without saturating. The mechanisms that enable this wide range of operation are not fully understood. We found that the amplitude of excitatory synaptic currents necessary to fire rodent pyramidal cells,...

A genetic pathway composed of Sox14 and Mical governs severing of dendrites during pruning

2 hours ago

Pruning that selectively eliminates neuronal processes is crucial for the refinement of neural circuits during development. In Drosophila, the class IV dendritic arborization neuron (ddaC) undergoes pruning to remove its larval dendrites during metamorphosis. We identified Sox14...

Adult generation of glutamatergic olfactory bulb interneurons

2 hours ago

The adult mouse subependymal zone (SEZ) harbors neural stem cells that are thought to exclusively generate GABAergic interneurons of the olfactory bulb. We examined the adult generation of glutamatergic juxtaglomerular neurons, which had dendritic arborizations that projected...

The pathways of interoceptive awareness

2 hours ago

A network of cortical brain regions, including the insula and anterior cingulate cortex (ACC), has been proposed as the critical and sole substrate for interoceptive awareness. Combining lesion and pharmacological approaches in humans, we found that the insula and ACC were not...

Request for Entries

Oct 16

Ask the Experts is your chance to get the answers to questions on applications, materials, methods, processes, and technologies. Email you question to bst_web@advantagemedia.com, and the editors of Bioscience Technology will find an appropriate expert to answer it. Watch this space in the future to see the questions your colleagues are posting.

STAY INFORMED: SUBSCRIBE TO

Magazine and E-mail Newsletters

Loading...
E-mail:   

MULTIMEDIA

Video:

Frontiers in Bioscience Learning and Memory Video

Oct 6

How does the brain learn and remember? An academic conference "Frontiers in Bioscience Learning and Memory" was held at City University of Hong Kong on June 16th.

Podcasts:

Allen Institute for Brain Research

Allen Institute for Brain Research

Oct 14

Discussed in this interview are both the mouse brain project and the human cortex project with an emphasis on the importance of these projects to neuroscience research.